Stavzor For Migraines Gets FDA’s OK
Well, it looks like 2008 going to be a good year for Noven Pharmaceuticals of Miami, Florida…and hopefully, those with migraines that can’t get relief from any current medication on the market. Remember back in October when Stavzor was crossing the final T’s and dotting the final i’s for FDA approval? Well, they got it. The official “okie -dokie” came through a couple of days after Christmas.
What Is Stavzor, Again?
For those of you with short memories (like me!) Stavzor is going to be the brand name of delayed release valporic acid. This drug is aimed for helping ease episodes of manic episodes. These fun epsiodes tend to come hand-in-hand with bipolar disorder. However, it is also been approved for treating epilepsy and as a preventative for migraines.
Stavzor for migraines would be used as a preventative medication only. It won’t do any good once a migraine is under way. It is hoped that a daily dosage (or whatever dosage your doctor recommends) will help keep migraines at bay. If you want to really impress your friends and eavesdroppers, the technical name for a preventative medicine is “prophylaxis.” Can you say “prophylaxis”, boys and girls? I know you can!
Stavzor for migraines is being aimed for adult migraineurs, as there is some question of it being too strong for children, especially those under the age of 2. It may cause liver damage in those so young.
The main delay in the release of Stavzor for migraines is that it also contains a drug called Depakote, made by Abbot Laboratories. Depokote also is a medication for migraines, epilespy, bipolar disorder and manic states. Apparantly, Depakote is under a copyright which doesn’t expire until this July. The earliest doctors can start perscribing Stavzor for migraines is in August. This is expected to be an expensive medication, but the exact prices are unknown at this time.
Stavzor is expected to come out in a quick dissolve capsule in various strengths.
Knock on wood that this works, eh?

August 3rd, 2008 at 11:38 am
[...] 2008 is shaping up to be a good year for more drug choice for migraine treatment. First, we had Stavzor approved in January, then it was announced that a generic Imitrex will hit the market in December [...]